Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers [Seeking Alpha]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Seeking Alpha
Current $6B valuation already prices in significant success, assuming $1–1.5B peak sales; management's $2.5B target requires broad label and strong market adoption. VIKTORIA-1 phase 3 data show gedatolisib offers best-in-class efficacy and manageable safety in wild-type patients, but mutant cohort results in Q2 2026 are the key catalyst. Risks include commercial execution against entrenched competitors, uncertain real-world adoption, and dependence on a single asset for value realization. This idea was discussed in more depth with members of my private investing community, The Total Pharma Tracker. Learn More » Vladislav Stepanov/iStock via Getty Images Introduction Celcuity's ( CELC ) Gedatolisib has shown outstanding data in a phase 3 trial called VIKTORIA-1 in HR-positive HER2 negative advanced breast cancer patients. The market is large and there's a key unmet need. However, at More on my IG service About the TPT service Thanks for reading. At the Total Pharma
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- Why Celcuity Stock Popped on Monday [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Why Celcuity Stock Popped on Monday [Yahoo! Finance]Yahoo! Finance
- Celcuity (CELC) is now covered by Citizens Jmp. They set an "outperform" rating and a $150.00 price target on the stock.MarketBeat
- Celcuity (CELC) is now covered by Citigroup Inc.. They set an "outperform" rating on the stock.MarketBeat
- Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally [Yahoo! Finance]Yahoo! Finance
CELC
Earnings
- 3/25/26 - Beat
CELC
Sec Filings
- 4/13/26 - Form 4
- 4/2/26 - Form ARS
- 4/2/26 - Form DEFA14A
- CELC's page on the SEC website